Company Overview
InMed Pharmaceuticals Inc. operates as a clinical stage pharmaceutical entity dedicated to developing a pipeline of prescription-based products within the United States market. The company executes its operations through two distinct segments, specifically InMed Pharmaceuticals and BayMedica Commercial, with the former focusing on research and development efforts for cannabino-related products. This enterprise is situated within the Healthcare sector, specifically classified under the Drug Manufacturers - Specialty & Generic industry, which implies a focus on specialized medicinal compounds rather than mass-market consumer goods. The company maintains a market capitalization of $1.91M, generates annual revenue of $4.51M, and employs a workforce of 13 individuals. These valuation and revenue figures indicate that the company functions as a micro-cap entity with limited operational scale, suggesting its financial stability and growth potential are heavily dependent on the successful advancement of its specific clinical pipeline and niche market positioning.
Financial Health
The company reports a trailing twelve-month revenue of $4.51M, yet it recorded a net income of -$7,664,363 and an EBITDA of -$7,630,413 during the same period. The significant disparity between the positive revenue of $4.51M and the substantial negative net income reveals a cost structure characterized by high operating expenses that far exceed total sales, a common trait for clinical stage firms investing heavily in research and development. Free cash flow stands at -$4,306,249, which indicates that the company is currently burning cash and lacks the internal liquidity to fund operations without external capital injections or asset sales. Despite the negative profitability metrics, the balance sheet holds $7.00M in cash against a debt obligation of $531,949. The debt-to-equity ratio is reported at 5.55, which suggests a highly leveraged financial position where debt significantly outweighs equity, though the existing cash reserves provide a buffer against immediate solvency risks. The gross margin is 29.7%, while the operating margin is -258.6% and the profit margin is -170.1%, indicating that while production costs are relatively contained, overhead and R&D expenses are consuming the majority of revenue. The current ratio is 5.94, a figure that indicates strong short-term liquidity and the ability to cover short-term obligations with current assets more than five times over. Return on Equity is -97.2% and Return on Assets is -49.8%, metrics that reveal that management effectiveness in generating profit from shareholder capital and assets is currently negative due to the company's developmental stage and accumulated losses.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to negative earnings, while the forward P/E is -0.10, implying that the market is pricing in expectations of future earnings recovery or is utilizing alternative valuation methods given the current lack of profitability. The price-to-book ratio is 0.19, which indicates that the company's market capitalization is trading at a significant discount to its book value, suggesting the market assigns low value to its tangible assets relative to its equity. The price-to-sales ratio is 0.42 and the EV/EBITDA is 0.60, alternative valuation metrics that suggest the company is valued on a revenue basis since earnings-based multiples are distorted by negative income. The stock has a 52-week high of $7.98 and a 52-week low of $0.59, providing a range within which the security has traded over the past year. Given the wide spread between the high and low, the current trading price sits within a broad volatility band, reflecting the speculative nature of a small-cap biotech firm. The beta value is 0.46, which means the stock's price volatility is less than half that of the broader market, indicating lower sensitivity to general market fluctuations compared to large-cap equities.
Growth & Income
The company exhibits a revenue growth rate of -26.2% year-over-year, while earnings growth is N/A due to the negative earnings baseline, implying that the business is currently contracting in terms of sales volume. Since the company does not pay dividends, indicated by a dividend yield of N/A and a payout ratio of 0.0%, it follows a strategy of reinvesting any potential earnings or utilizing cash reserves into growth initiatives rather than distributing income to shareholders. The negative revenue growth combined with the lack of dividend income characterizes a high-risk, high-reward profile typical of clinical stage pharmaceutical companies that prioritize asset development over immediate shareholder returns. Overall, the growth and income profile is defined by negative sales momentum and a complete absence of current income generation, reflecting the company's status as a pre-revenue or early-stage development entity reliant on future product approvals to reverse its financial trajectory.